Claude Bertrand quits post with Ipsen for pastures new

12 December 2016

French pharma company Ipsen (Euronext: IPN) today announced that Claude Bertrand, executive vice president, R&D, chief scientific officer, will depart Ipsen on January, 2017, to join another company, which was not named.

Pending Dr Bertrand’s replacement, Alexandre Lebeaut will lead the R&D division in the interim. Dr Lebeaut, senior vice president, global drug development, joined Ipsen in 2012, managerial experience after having spent more than 20 years in large pharmaceutical and biotechnology companies, with extensive international experience in Italy, France and mostly North America.

Commenting on the news, Ipsen chief executive David Meek said: “On behalf of the company, I would like to thank Dr Bertrand for his significant contribution to leading the R&D organization during the past seven years. We wish him well as he moves on to pursue a new opportunity. We are fortunate to have an experienced and successful R&D leader like Dr Lebeaut to step up and lead the R&D team.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK